{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:45:06Z","timestamp":1792788306143,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Massachusetts Institute of Technology","id":[{"id":"https:\/\/ror.org\/042nb2s44","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The COVID-19 pandemic exposed a recurring vulnerability within translational medicine: early therapeutic signals can acquire clinical, public, and institutional authority before the evidentiary pathway has established pharmacologic plausibility, evidence quality, clinical efficacy, and appropriate use. This Commentary proposes\n                    <jats:bold>translational stewardship<\/jats:bold>\n                    as an upstream response. Its central claim is that positive therapeutic signals and their critical plausibility constraints should co-travel through the translational pathway. A positive biological signal and a clinically plausible therapeutic signal are different evidentiary objects; when that distinction is lost, perceived therapeutic readiness can exceed evidentiary maturity. Ivermectin provides a concentrated case study. An initial in vitro antiviral finding generated a legitimate but low-confidence repurposing signal, while subsequent pharmacokinetic and pharmacodynamic analyses substantially constrained the plausibility of direct antiviral efficacy at clinically achievable exposures. Early clinical evidence was heterogeneous and fragile, portions of the evidence base were later affected by data-integrity concerns, and larger randomized trials did not demonstrate clinically meaningful benefit. Nevertheless, ivermectin acquired credibility through unstable evidence synthesis, clinical advocacy, public amplification, and institutional-distrust narratives. The broader lesson is not that early signals should be suppressed, but that critical constraints should be encoded, preserved, and propagated before provisional findings acquire durable therapeutic authority.\n                  <\/jats:p>","DOI":"10.1186\/s12967-026-08595-z","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T09:25:15Z","timestamp":1783589115000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Translational stewardship in pandemic therapeutics: ivermectin, evidentiary misalignment, and the propagation of constraints"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2427-8803","authenticated-orcid":false,"given":"Harlan","family":"Breindel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"issue":"6","key":"8595_CR1","doi-asserted-by":"publisher","first-page":"e19659","DOI":"10.2196\/19659","volume":"22","author":"V Tangcharoensathien","year":"2020","unstructured":"Tangcharoensathien V, Calleja N, Nguyen T, Purnat T, D\u2019Agostino M, Garcia-Saiso S, et al. Framework for managing the COVID-19 infodemic: methods and results of an online, crowdsourced WHO technical consultation. J Med Internet Res. 2020;22(6):e19659. https:\/\/doi.org\/10.2196\/19659.","journal-title":"J Med Internet Res"},{"issue":"6","key":"8595_CR2","doi-asserted-by":"publisher","first-page":"e21820","DOI":"10.2196\/21820","volume":"22","author":"G Eysenbach","year":"2020","unstructured":"Eysenbach G. How to fight an infodemic: the four pillars of infodemic management. J Med Internet Res. 2020;22(6):e21820. https:\/\/doi.org\/10.2196\/21820.","journal-title":"J Med Internet Res"},{"issue":"5","key":"8595_CR3","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/aje\/kwq211","volume":"172","author":"MJ Khoury","year":"2010","unstructured":"Khoury MJ, Gwinn M, Ioannidis JPA. The emergence of translational epidemiology: from scientific discovery to population health impact. Am J Epidemiol. 2010;172(5):517\u201324. https:\/\/doi.org\/10.1093\/aje\/kwq211.","journal-title":"Am J Epidemiol"},{"issue":"2","key":"8595_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1539-6924.1988.tb01168.x","volume":"8","author":"RE Kasperson","year":"1988","unstructured":"Kasperson RE, Renn O, Slovic P, Brown HS, Emel J, Goble R, et al. The social amplification of risk: a conceptual framework. Risk Anal. 1988;8(2):177\u201387. https:\/\/doi.org\/10.1111\/j.1539-6924.1988.tb01168.x.","journal-title":"Risk Anal"},{"key":"8595_CR5","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1056\/NEJMoa2022926","volume":"383","author":"RECOVERY Collaborative Group","year":"2020","unstructured":"RECOVERY Collaborative Group. Effect of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;383:2030\u201340. https:\/\/doi.org\/10.1056\/NEJMoa2022926.","journal-title":"N Engl J Med"},{"key":"8595_CR6","doi-asserted-by":"publisher","first-page":"173556","DOI":"10.1016\/j.ejphar.2020.173556","volume":"889","author":"R Huang","year":"2020","unstructured":"Huang R, Zhu C, Wang J, Xue L, Li C, Yan X, et al. Corticosteroid therapy is associated with the delay of SARS-CoV-2 clearance in COVID-19 patients. Eur J Pharmacol. 2020;889:173556. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173556.","journal-title":"Eur J Pharmacol"},{"key":"8595_CR7","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"RECOVERY Collaborative Group","year":"2021","unstructured":"RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693\u2013704. https:\/\/doi.org\/10.1056\/NEJMoa2021436.","journal-title":"N Engl J Med"},{"key":"8595_CR8","doi-asserted-by":"publisher","first-page":"971017","DOI":"10.3389\/fphar.2022.971017","volume":"13","author":"Z Lu","year":"2022","unstructured":"Lu Z, Wang Z, Song Z, Chen C, Ma H, Gong P, Xu Y. Single-cell sequencing of brain tissues reveal the central nervous system\u2019s susceptibility to SARS-CoV-2 and the drug. Front Pharmacol. 2022;13:971017. https:\/\/doi.org\/10.3389\/fphar.2022.971017.","journal-title":"Front Pharmacol"},{"key":"8595_CR9","doi-asserted-by":"publisher","first-page":"104787","DOI":"10.1016\/j.antiviral.2020.104787","volume":"178","author":"L Caly","year":"2020","unstructured":"Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787. https:\/\/doi.org\/10.1016\/j.antiviral.2020.104787.","journal-title":"Antiviral Res"},{"issue":"4","key":"8595_CR10","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/cpt.1889","volume":"108","author":"VD Schmith","year":"2020","unstructured":"Schmith VD, Zhou JJ, Lohmer LRL. The approved dose of ivermectin alone is not the ideal dose for the treatment of COVID-19. Clin Pharmacol Ther. 2020;108(4):762\u20135. https:\/\/doi.org\/10.1002\/cpt.1889.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"8595_CR11","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1111\/bcp.14476","volume":"87","author":"R Pe\u00f1a-Silva","year":"2021","unstructured":"Pe\u00f1a-Silva R, Duffull SB, Steer AC, Jaramillo-Rincon SX, Gwee A, Zhu X. Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID-19. Br J Clin Pharmacol. 2021;87(3):1589\u201390. https:\/\/doi.org\/10.1111\/bcp.14476.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"8595_CR12","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1002\/cpt.1909","volume":"108","author":"U Arshad","year":"2020","unstructured":"Arshad U, Pertinez H, Box H, Tatham L, Rajoli RKR, Curley P, et al. Prioritization of anti-SARS-CoV-2 drug repurposing opportunities based on plasma and target-site concentrations derived from their established human pharmacokinetics. Clin Pharmacol Ther. 2020;108(4):775\u201390. https:\/\/doi.org\/10.1002\/cpt.1909.","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"8595_CR13","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1177\/009127002237994","volume":"42","author":"CA Guzzo","year":"2002","unstructured":"Guzzo CA, Furtek CI, Porras AG, Chen C, Tipping R, Clineschmidt CM, Sciberras DG, Hsieh JY-K, Lasseter KC. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol. 2002;42(10):1122\u201333. https:\/\/doi.org\/10.1177\/009127002237994.","journal-title":"J Clin Pharmacol"},{"key":"8595_CR14","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1038\/s41591-021-01535-y","volume":"27","author":"JM Lawrence","year":"2021","unstructured":"Lawrence JM, Meyerowitz-Katz G, Heathers JAJ, Brown NJL, Sheldrick KA. The lesson of ivermectin: meta-analyses based on summary data alone are inherently unreliable. Nat Med. 2021;27:1853\u20134. https:\/\/doi.org\/10.1038\/s41591-021-01535-y.","journal-title":"Nat Med"},{"issue":"3","key":"8595_CR15","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/bmjebm-2021-111678","volume":"27","author":"LI Garegnani","year":"2022","unstructured":"Garegnani LI, Madrid E, Meza N. Misleading clinical evidence and systematic reviews on ivermectin for COVID-19. BMJ Evid Based Med. 2022;27(3):156\u20138. https:\/\/doi.org\/10.1136\/bmjebm-2021-111678.","journal-title":"BMJ Evid Based Med"},{"issue":"6","key":"8595_CR16","doi-asserted-by":"publisher","first-page":"CD015017","DOI":"10.1002\/14651858.CD015017.pub3","volume":"6","author":"M Popp","year":"2022","unstructured":"Popp M, Reis S, Schiesser S, Hausinger RI, Stegemann M, Metzendorf M-I, et al. Ivermectin for preventing and treating COVID-19. Cochrane Database Syst Rev. 2022;6(6):CD015017. https:\/\/doi.org\/10.1002\/14651858.CD015017.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"8595_CR17","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.31546\/2633-8653.1007","volume":"2","author":"H Carvallo","year":"2020","unstructured":"Carvallo H, Hirsch R, Psaltis A, Contreras V. Study of the efficacy and safety of topical ivermectin + iota-carrageenan in the prophylaxis against COVID-19 in health personnel. J Biomedical Res Clin Invest. 2020;2(1):1007. https:\/\/doi.org\/10.31546\/2633-8653.1007.","journal-title":"J Biomedical Res Clin Invest"},{"key":"8595_CR18","unstructured":"Centers for Disease Control and Prevention. Rapid increase in ivermectin prescriptions and reports of severe illness associated with use of products containing ivermectin to prevent or treat COVID-19. Health Alert Network CDCHAN-00449. 26 August 2021."},{"issue":"3","key":"8595_CR19","doi-asserted-by":"publisher","first-page":"e299","DOI":"10.1097\/MJT.0000000000001377","volume":"28","author":"P Kory","year":"2021","unstructured":"Kory P, Meduri GU, Varon J, Iglesias J, Marik PE. Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19. Am J Ther. 2021;28(3):e299\u2013318. https:\/\/doi.org\/10.1097\/MJT.0000000000001377.","journal-title":"Am J Ther"},{"key":"8595_CR20","unstructured":"Kory P, U.S. senate committee on homeland security and governmental affairs. oral testimony. In: Early outpatient treatment: an essential part of a COVID-19 solution, Part II. Full Committee Hearing; 2020; Washington, DC and videoconference. Available from: U.S. Senate Committee on Homeland Security and Governmental Affairs website. Accessed 2026 Jun 18."},{"issue":"4","key":"8595_CR21","doi-asserted-by":"publisher","first-page":"e434","DOI":"10.1097\/MJT.0000000000001402","volume":"28","author":"A Bryant","year":"2021","unstructured":"Bryant A, Lawrie TA, Dowswell T, Fordham EJ, Mitchell S, Hill SR, Tham TC. Ivermectin for prevention and treatment of COVID-19 infection: a systematic review, meta-analysis, and trial sequential analysis to inform clinical guidelines. Am J Ther. 2021;28(4):e434\u201360. https:\/\/doi.org\/10.1097\/MJT.0000000000001402.","journal-title":"Am J Ther"},{"key":"8595_CR22","doi-asserted-by":"publisher","unstructured":"Manu P. Expression of Concern for Kory, Meduri P, Varon GU, Iglesias J, Marik J. PE. Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19. Am J Ther. 2022;29(2):e231. https:\/\/doi.org\/10.1097\/MJT.0000000000001481.","DOI":"10.1097\/MJT.0000000000001481"},{"issue":"2","key":"8595_CR23","doi-asserted-by":"publisher","first-page":"e232","DOI":"10.1097\/MJT.0000000000001482","volume":"29","author":"P Manu","year":"2022","unstructured":"Manu P. Expression of Concern for Bryant A, Lawrie TA, Dowswell T, Fordham EJ, Mitchell S, Hill SR, Tham TC. Ivermectin for prevention and treatment of COVID-19 infection: a systematic review, meta-analysis, and trial sequential analysis to inform clinical guidelines. Am J Ther. 2022;29(2):e232. https:\/\/doi.org\/10.1097\/MJT.0000000000001482.","journal-title":"Am J Ther"},{"issue":"1","key":"8595_CR24","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1097\/MJT.0000000000001461","volume":"29","author":"SG Rothrock","year":"2022","unstructured":"Rothrock SG, Weber KD, Giordano PA. Meta-analyses do not establish improved mortality with ivermectin use in COVID-19. Am J Ther. 2022;29(1):e87\u201394. https:\/\/doi.org\/10.1097\/MJT.0000000000001461.","journal-title":"Am J Ther"},{"issue":"10","key":"8595_CR25","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1093\/jamia\/ocac114","volume":"29","author":"Y Hua","year":"2022","unstructured":"Hua Y, Jiang H, Lin S, Yang J, Plasek JM, Bates DW, Zhou L. Using Twitter data to understand public perceptions of approved versus off-label use for COVID-19-related medications. J Am Med Inf Assoc. 2022;29(10):1668\u201378. https:\/\/doi.org\/10.1093\/jamia\/ocac114.","journal-title":"J Am Med Inf Assoc"},{"issue":"3","key":"8595_CR26","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1093\/pubmed\/fdac152","volume":"45","author":"AM Ostrovsky","year":"2023","unstructured":"Ostrovsky AM, Parikh C. Impact of misinformation on ivermectin internet searches and prescribing trends during COVID-19. J Public Health (Oxf). 2023;45(3):631\u20135. https:\/\/doi.org\/10.1093\/pubmed\/fdac152.","journal-title":"J Public Health (Oxf)"},{"issue":"9","key":"8595_CR27","doi-asserted-by":"publisher","first-page":"e233257","DOI":"10.1001\/jamahealthforum.2023.3257","volume":"4","author":"RH Perlis","year":"2023","unstructured":"Perlis RH, Lunz Trujillo K, Green J, Safarpour A, Druckman JN, Santillana M, Ognyanova K, Lazer D. Misinformation, trust, and use of ivermectin and hydroxychloroquine for COVID-19. JAMA Health Forum. 2023;4(9):e233257. https:\/\/doi.org\/10.1001\/jamahealthforum.2023.3257.","journal-title":"JAMA Health Forum"},{"issue":"18","key":"8595_CR28","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1056\/NEJMoa2115869","volume":"386","author":"G Reis","year":"2022","unstructured":"Reis G, Silva EASM, Silva DCM, Thabane L, Milagres AC, Ferreira TS, et al. Effect of early treatment with ivermectin among patients with Covid-19. N Engl J Med. 2022;386(18):1721\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2115869.","journal-title":"N Engl J Med"},{"issue":"11","key":"8595_CR29","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1001\/jama.2023.1650","volume":"329","author":"S Naggie","year":"2023","unstructured":"Naggie S, Boulware DR, Lindsell CJ, Stewart TG, Gentile N, Collins S, et al. Effect of higher-dose ivermectin for 6 days vs placebo on time to sustained recovery in outpatients with COVID-19: a randomized clinical trial. JAMA. 2023;329(11):888\u201397. https:\/\/doi.org\/10.1001\/jama.2023.1650.","journal-title":"JAMA"},{"key":"8595_CR30","unstructured":"World Health Organization. WHO advises that ivermectin only be used to treat COVID-19 within clinical trials. 31 March 2021."},{"key":"8595_CR31","unstructured":"Merck. Merck statement on ivermectin use during the COVID-19 pandemic. 4 February 2021."},{"key":"8595_CR32","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP, STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology statement: guidelines for reporting observational studies. BMJ. 2007;335:806\u20138. https:\/\/doi.org\/10.1136\/bmj.39335.541782.AD.","journal-title":"BMJ"},{"key":"8595_CR33","doi-asserted-by":"publisher","first-page":"c332","DOI":"10.1136\/bmj.c332","volume":"340","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. BMJ. 2010;340:c332. https:\/\/doi.org\/10.1136\/bmj.c332.","journal-title":"BMJ"},{"issue":"3","key":"8595_CR34","doi-asserted-by":"publisher","first-page":"030201","DOI":"10.11613\/BM.2017.030201","volume":"27","author":"A Mlinari\u0107","year":"2017","unstructured":"Mlinari\u0107 A, Horvat M, \u0160upak Smol\u010di\u0107 V. Dealing with the positive publication bias: why you should really publish your negative results. Biochem Med (Zagreb). 2017;27(3):030201. https:\/\/doi.org\/10.11613\/BM.2017.030201.","journal-title":"Biochem Med (Zagreb)"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08595-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08595-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08595-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:03:09Z","timestamp":1791241389000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08595-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8595"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08595-z","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"9 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During drafting and revision, the author used OpenAI ChatGPT (GPT-5.5 Thinking; accessed May, June 2026) for editorial assistance on the final draft to review for clarity, proofreading errors, and formatting support, and to assist with source discovery. All sources were independently verified, reviewed, and employed in the text. The author takes full responsibility for the manuscript.","order":3,"name":"Ethics","label":"Use of AI-assisted technologies","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author is a retired Lecturer in Comparative Media Studies\/Writing at the Massachusetts Institute of Technology, where he taught and researched scientific and technical communication and analysis in the Writing, Rhetoric, and Professional Communication program, working alongside technical faculty across disciplines, including bioengineering where he helped usher therapeutic projects from bench to bedside.","order":4,"name":"Ethics","label":"Authors\u2019 information","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declares that he has no competing interests.","order":5,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1243"}}